Virtual Library

Start Your Search

  • ELCC 2018

    The 8th European Lung Cancer Conference

    Access to all presentations that took place at ELCC 2018 in Geneva, Switzerland

    Presentation Date(s):  
    • Apr 11 - 14, 2018
    • Total Presentations: 407

Filter Results:

Show Only Available Presentations

  • +

    First line for oncogene addicted lung cancer

    • Type: Educational session
    • Presentations: 5
    • Moderators:J. Wolf
    • Coordinates: 4/11/2018, 14:30 - 16:00, Room B
    • +

      The role of first-line combination therapy for oncogene addicted lung cancer

      15:30 - 15:50  |  Presenter: T. Seto

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Immunotherapy and next-generation TKIs: From second to frontline treatment

    • Type: Poster Discussion session
    • Presentations: 18
    • +

      141PD - A prospective study of molecular testing status in the EGFR mutation positive NSCLC patients with disease progression during EGFR TKI treatment (REMEDY study)

      10:54 - 10:54  |  Presenter: K. Kanai

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    New approaches in rare thoracic tumors

    • Type: Proffered Paper session
    • Presentations: 6
    • Moderators:M. Perol
    • Coordinates: 4/13/2018, 11:00 - 12:30, Room A
    • +

      112O - Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505)

      11:25 - 11:40  |  Presenter: T. Seto

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.